9 1 7 a r t I C l e S Cancer pain markedly impairs the quality of life in patients. Breast, lung and prostate cancers frequently metastasize to bones and cause bone cancer pain by releasing algogenic substances. These substances include protons, bradykinin, endothelins, prostaglandins, proteases and growth factors such as nerve growth factor (NGF) and vascular endothelial growth factor (VEGF) [1] [2] [3] [4] that can interact with peripheral nerves and cause increased hypersensitivity and excitability of nociceptive neurons (nociceptors) 3, 5, 6 . NGF and VEGF also induce outgrowth of pain-conducting nerve fibers in cancer affected areas 3, 4 . Despite the focus on cancer-produced pronociceptive mediators 7 , early-stage cancers before metastasis to bone are often not painful 2, 8 and pain in melanoma is not common before metastasis 9 . It is conceivable that different cancers and even the same cancers at different growth stages may produce different pain mediators that can differentially regulate pain sensitivity via positive or negative modulation 10 .
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VOLUME 20 | NUMBER 7 | JULY 2017 nature neurOSCIenCe a r t I C l e S typical biphasic inflammatory pain, as previously reported 27 , but the second-phase pain (10-45 min) was substantially inhibited by PD-L1 pretreatment (i.pl., 1-10 µg, P < 0.05, one-way ANOVA), in a dosedependent manner (Fig. 1a) . At high doses (5 and 10 µg), PD-L1 also caused a mild inhibition of the first-phase pain (Fig. 1a) .
Next we tested whether PD-L1 would also alter pain threshold in naive mice. The von Frey test revealed a significant increase in paw withdrawal threshold after i.pl. injection of PD-L1 (5 µg, ~0.1 nmol, P < 0.05, two-way ANOVA). The threshold increase was rapid and evident at 30 min and was maintained for 3 h after the injection (Fig. 1b) . Since we injected a chimeric PD-L1 fusion protein with human immunoglobulin G (IgG) at the C terminus, we used human IgG as an inactive control. This human IgG had no effect on the pain threshold (Fig. 1b) .
PD-L1 is an endogenous pain inhibitor and alters basal pain thresholds via PD-1 PD-L1 is produced by malignant tissues and serves as a predictive biomarker in cancer immunotherapy 28 . As expected, mouse B16 melanoma tissue has high expression of PD-L1 (~450 ng/mg tissue, Fig. 2a) , as evaluated by ELISA. PD-L1 was also secreted in culture medium of melanoma cells (Supplementary Fig. 1a ). To determine whether normal tissues also produce PD-L1, we compared PD-L1 contents in non-neural and neural tissues. Non-neural tissues, such as liver, spleen and kidney, had high levels of PD-L1 (~70-90 ng/mg tissue; Fig. 2a ). Neural tissues, including brain, spinal cord and DRG had PD-L1 levels around 50 ng/mg tissue (Fig. 2a) . Furthermore, we detected PD-L1 in the sciatic nerve and hindpaw skin tissues (Fig. 2a) , which contain pain-sensing nerve fibers. These results suggest that PD-L1 is broadly synthesized by neural and skin tissue. In agreement, in situ hybridization revealed Pdl1 mRNA expression in mouse DRG neurons ( Supplementary Fig. 1b,c) .
To determine whether endogenous PD-L1, produced by nonmalignant tissues, regulates pain, we tested mechanical pain after pharmacological blockade of either PD-L1 or PD-1 in naive mice. Neutralization of hindpaw PD-L1 by i.pl. injection of soluble PD-1 (sPD-1, 5 µg, ~0.1 nmol) induced a transient mechanical allodynia for 3 h (Fig. 2b) , without causing spontaneous pain a r t I C l e S (Supplementary Fig. 2a) . Blockade of PD-1 with a mouse anti-PD-1 antibody, RMP1-14 (5 µg, ~0.1 nmol, i.pl.), also induced mechanical allodynia for 3 h (Fig. 2b) . Nivolumab (Opdivo) is a US Food and Drug Administrationapproved fully humanized IgG4 monoclonal antibody that selectively targets PD-1 (ref. 29) and has shown success in treating melanoma, lymphoma and lung cancer 17, 29, 30 . Of note, nivolumab (10 µg, ~0.07 nmol, i.pl.), but not control human IgG, induced marked mechanical allodynia for 5 h (Fig. 2b) . PD-L1's analgesic effects were blocked by both RMP-14 and nivolumab ( Supplementary  Fig. 2b ), suggesting that PD-L1 inhibits pain via PD-1. As a human antibody, nivolumab showed cross-reactivity in mouse tissue and binding to DRG neurons and sciatic nerve fibers in wild-type (WT) mice. This binding was absent in Pd1 knockout mice (Pd1 −/− ; Supplementary Fig. 2c ).
Next we tested baseline pain and PD-L1-induced analgesia in Pd1 −/− mice with and without PD-L1 treatment. Notably, baseline pain sensitivity was elevated in naive Pd1 −/− mice. Compared with WT mice, Pd1 −/− mice displayed mechanical and thermal hypersensitivity, showing decreased mechanical and thermal pain thresholds in the von Frey test and hot plate test (Fig. 2c,d ). This result indicates that PD-1 regulates basal pain sensitivity. As expected, both the PD-L1-induced analgesic effect and RMP1-14-induced hyperalgesic effect were abolished in Pd1 −/− mice ( Supplementary Fig. 3a,b) . Notably, Pd1 −/− mice showed no developmental defects in sensory neurons and their innervations. The central innervations of primary afferents in the spinal cord dorsal horn were comparable in WT and knockout mice (Supplementary Fig. 4 ). The distribution patterns of primary sensory neurons, including small-sized nociceptive neurons (CGRP + peptidergic neurons and IB4 + nonpeptidergic neurons) a r t I C l e S and large-sized A-fiber DRG neurons (NF200 + ), as well as the total population of sensory neurons, were also unaltered in DRG tissues of knockout mice (Supplementary Fig. 5 ). Taken together, these findings in WT and Pd1 −/− mice strongly suggest that (i) PD-L1 is an endogenous inhibitor of pain, (ii) PD-L1 produces analgesia via PD-1, and (iii) altered pain sensitivity in Pd1 −/− mice is not a result of developmental defects in sensory neurons.
PD-1 receptor is expressed by primary sensory neurons in mouse DRGs
To determine peripheral mechanisms by which PD-L1 modulates pain, we examined Pd1 mRNA and PD-1 protein expression in mouse DRG neurons. In situ hybridization showed Pd1 mRNA expression in most DRG neurons, regardless of size (Fig. 3a,b) . This signal was absent in Pd1 −/− mice ( Fig. 3c) and in DRG sections treated with sense control probe (Fig. 3d) , confirming the specificity of Pd1 mRNA expression. Immunohistochemistry revealed PD-1 immunoreactivity in most DRG neurons (Fig. 3e) . The specificity of the PD-1 antibody was validated by loss of PD-1 immunostaining in DRG neurons of Pd1 −/− mice ( Fig. 3e) and further confirmed by absence of staining in WT DRG after co-incubation of the antibody with a blocking peptide (Fig. 3e) . Size frequency analysis showed a broad expression of PD-1 by DRG neurons with small, medium and large sizes (Fig. 3f) . Double staining confirmed PD-1 expression in both large-diameter A-fiber neurons (NF200 + ) and small-diameter C-fiber neurons (NF200 − , Fig. 3g ). PD-1 immunoreactivity was present in NF200 + and NF200 − axons in the sciatic nerve, indicating axonal transport of PD-1 from DRG cell bodies to peripheral axons (Fig. 3h) . PD-1-immunoreactive axons coexpressed CGRP, a marker for nociceptive peptidergic neurons (Fig. 3i) . Together, these results demonstrate that primary sensory neurons, including nociceptors and their axons, express PD-1, providing a neuronal basis for PD-1 modulation of pain.
PD-L1 suppresses nociceptive neuron activity in mouse DRGs via PD-1 Activation and sensitization of nociceptive sensory neurons (nociceptors) often produces pain and pain hypersensitivity [31] [32] [33] . We postulated that PD-L1-PD-1signaling inhibits pain via direct modulation of nociceptor activity. We used patch clamp recordings to evaluate excitability in dissociated small-diameter neurons (<25 µm, presumably nociceptors) in mouse DRGs. Notably, PD-L1, at a very low concentration (10 ng/ml, ~0.2 nM), evoked a potent and immediate inhibition of action potentials, induced by current injection, and also increased the rheobase, a minimum current to induce action potential (Fig. 4a) . PD-L1 also induced hyperpolarization of the resting membrane potential (RMP) in DRG neurons (Fig. 4b) . These effects of PD-L1 on action potentials and RMPs were abrogated in Pd1 −/− mice, indicating that PD-L1 modulates neuronal excitability through PD-l (Fig. 4a,b) . Furthermore, Pd1-deficient nociceptive neurons displayed increased RMP and firing frequency of action potentials (Fig. 4c,d) , suggesting that the intrinsic excitability of nociceptors is enhanced in Pd1 mutant mice. 
a r t I C l e S
To further assess the contribution of endogenous PD-L1 and PD-1 to neuronal excitability in WT neurons, we used pharmacological approaches in a whole-mount DRG preparation. Compared to dissociated DRG neurons, the whole-mount DRG preparation has the advantage of retaining extracellular PD-L1. Neutralization of PD-L1 with sPD-1 (30 ng/ml, ~0.6 nM) increased the firing rate of action potentials in small-diameter DRG neurons (Fig. 4e) . Blocking the function of PD-1 with nivolumab, but not the control IgG (300 ng/ml, ~2 nM), also increased the firing rate (Fig. 4f) . Together, both gain-of-function and loss-of-function approaches demonstrate that PD-L1 and PD-1 are critical in regulating excitability of nociceptive neurons.
PD-L1 inhibits neuronal hyperexcitability and neuropathic pain after nerve injury Hyperexcitability of primary sensory neurons after nerve injury has been strongly implicated in chronic pain 31, [33] [34] [35] . We used the whole-mount mouse DRG preparation to examine hyperexcitability in small-sized nociceptive neurons after chronic nerve constriction injury (CCI). As expected, nociceptive neurons fired more action potentials after CCI (Fig. 5a) . Notably, nerve injury-induced hyperexcitability (increased firing rate of action potentials) of DRG neurons was dose-dependently suppressed by PD-L1 (1-10 ng/ml, ~0.02-0.2 nM; Fig. 5a,b) .
The central axons of nociceptive neurons terminate in the spinal cord dorsal horn to form first-order synapses in the pain pathway 33 . PD-L1 in DRG neurons could be transported to central axon terminals to modulate spinal cord synaptic transmission and nociception. To test this hypothesis, we examined the effects of intrathecal (i.t.) injection of PD-L1 on CCI-induced neuropathic pain in mice. PD-L1 reduced the CCI-induced mechanical allodynia at a low dose (100 ng; Fig. 6a ). These interneurons form a nociceptive circuit with C-fiber afferents and projection neurons 36, 37 . By sharp contrast, exposure of spinal cord slices to sPD-1 (PD-L1 neutralization) and nivolumab (PD-1 blockade) increased sEPSC frequency in lamina IIo neurons ( Supplementary Fig. 6b,c) . As expected, PD-L1's inhibition of sEPSC frequency was blocked by nivolumab ( Supplementary Fig. 6d ). Thus, PD-L1-PD-1 signaling also has an active role in modulating spinal nociceptive transmission.
Next we tested the central effects of PD-L1 in a bone cancer model in rats 38 . PD-L1, given two weeks after tumor cell inoculation via i.t. route, reduced bone cancer-induced mechanical allodynia (P < 0.05, two-way ANOVA, Supplementary Fig. 7a) . Moreover, bone cancerinduced hyperexcitability of wide dynamic range (WDR) neurons in dorsal horn neurons was suppressed by PD-L1 ( Supplementary  Fig. 7b,c) , whereas nivolumab enhanced activities of WDR neurons ( Supplementary Fig. 7d,e) . Taken together, our data suggest that PD-L1 is a neuromodulator in both the peripheral and central nervous system; and in the spinal cord PD-L1 regulates acute and chronic pain by suppressing nociceptive synaptic transmission and injury-induced neuronal plasticity in dorsal horn neurons via PD-1 receptor. a r t I C l e S PD-L1 modulates sodium currents and TREK2 potassium channels via SHP-1 How does PD-L1 modulate neuronal excitability? Activation of PD-1 by PD-L1 recruits the tyrosine phosphatases SHP-1and SHP-2 (Src homology region 2 domain-containing phosphatase-1 and 2) to mediate PD-L1's biological actions in immune cells 13, 39 . Immunohistochemistry shows that PD-L1 is sufficient to activate SHP-1 in vivo after i.t. injection, leading to increased phosphorylation of SHP-1 (pSHP-1) in mouse DRG neurons (Fig. 6a) . In agreement, pSHP-1 colocalized with Pd1 mRNA in DRG neurons ( Supplementary Fig. 8a,b) . Moreover, PD-L1-induced SHP-1 phosphorylation was blocked by the SHP-1 inhibitor sodium stibogluconate (SSG) in dissociated DRG neurons (Supplementary Fig. 8c ). Intraplantar administration of PD-L1 induced analgesia by reducing paw withdrawal frequency in naive animals; but this analgesic effect of PD-L1 was abolished by i.pl. SSG (Fig. 6b) . Thus, SHP-1 is not only a downstream signaling event following PD-1 activation in DRG neurons but also contributes to PD-L1-evoked analgesia.
Given an important role of sodium channels in generating action potentials and pain 40 , we examined the effects of PD-L1 on transient sodium currents in mouse DRG neurons with small diameters. PD-L1 perfusion (10 ng/ml) caused a gradual and persistent inhibition of transient sodium currents (Fig. 6c) . Moreover, PD-L1-induced inhibition of sodium currents was partially blocked by the SHP inhibitor SSG (Fig. 6c) , supporting an involvement of SHP.
The two-pore K + channel TREK2 regulates RMP in DRG nociceptive neurons of rats 41 . TREK2 also expressed in mouse DRG neurons (Supplementary Fig. 9a ). We assessed whether PD-L1 would modulate TREK2 activity in heterologous CHO cells. PD-L1 caused hyperpolarization of RMP (∆RMP ≈ 8 mV) in CHO cells coexpressing PD-1 (encoded by PD1, also known asPDCD1) and TREK2 (encoded by KCNK10), but this change was blocked by SSG (Fig. 6d) . PD-L1 also potentiated TREK2-induced currents and produced a negative shift in reversal potential in CHO cells coexpressing PD-1 and TREK2, and both these effects were abolished by SSG (Fig. 6e) . However, PD-L1 alone was insufficient to alter the voltage-ramp currents and reversal potential in CHO cells expressing either TREK2 or PD-1 (Supplementary Fig. 9b) . Collectively, activation of PD-1 by PD-L1 might modulate neuronal excitability by suppressing the function of sodium channels and enhancing the function of potassium channels (TREK2) via SHP-1 (Supplementary Fig. 9c ).
Human DRG neurons express functional PD-1 A translational gap from rodents to humans has been blamed for many failures in developing pain therapeutics 42, 43 . We therefore examined the PD-1 expression and function in human DRG neurons from disease-free donors, as shown in our previous studies 25, 44 . PD-1 immunoreactivity was observed on the cell surface of human DRG neurons of small and large sizes, as well as in human spinal nerve axons (Fig. 7a and Supplementary Fig. 10a,b) . This staining in human DRG and nerve sections was abolished upon blockade by the immunizing peptide (Supplementary Fig. 10a,b) . Both a r t I C l e S NF200-positive and NF200-negative axons of human spinal nerve expressed PD-1 (Supplementary Fig. 10c ).
We found PD-1 receptor to be functional in human DRG neurons: incubation of dissociated small-diameter nociceptive neurons (30-50 µm) with PD-L1 directly altered neuronal activity. At a concentration that is effective in suppressing mouse nociceptive neuron activity (10 ng/ml; Fig. 4a,b) , PD-L1 markedly inhibited the firing frequency of action potentials and further increased the threshold for action potential induction (rheobase) in human DRG neurons (Fig. 7b,c) . PD-L1 also caused hyperpolarization of human nociceptive neurons by decreasing RMP (Fig. 7d) . Additionally, PD-L1 perfusion (10 ng/ml) caused a gradual and persistent inhibition of transient sodium currents in human DRG neurons (Fig. 7e) . Notably, PD-L1-induced inhibition of sodium currents was partially blocked by SSG in mouse DRG neurons (Fig. 6c) but completely blocked by SSG in human DRG neurons (Fig. 7e) , suggesting that SHP is important in regulating PD-L1 signaling in human sensory neurons.
PD-L1 and PD-1 mask spontaneous pain and allodynia in a mouse melanoma model Given the high expression of PD-L1 in melanoma (Fig. 2a) , we examined the contribution of PD-L1 and PD-1 to altered pain sensitivity in a mouse model of melanoma. Intraplantar injection of mouse melanoma cells (5 × 10 5 cells in 20 µl) into C57BL/6 mice led to time-dependent tumor growth in a hindpaw, showing a threefold increase in paw volume 4 weeks after melanoma cell implantation (MCI-4w, Fig. 8a ). Melanoma-bearing mice also exhibited increased PD-L1 levels in serum at MCI-4w (Fig. 8b) . Despite profound tumor growth, we did not observe cardinal features of cancer pain, including mechanical allodynia and spontaneous pain (licking or flinching of the tumor-bearing paw) (Fig. 8c,d) .
Next we tested the hypothesis that pain after melanoma could be masked by upregulated PD-L1 function. We employed several pharmacological approaches to block PD-L1-PD-1 signaling. Strikingly, local neutralization of PD-L1, by i.pl. injection of soluble PD-1 (sPD-1, 5 µg, MCI-4w) elicited marked spontaneous pain (Fig. 8e) . The onset of spontaneous pain was very rapid: mice displayed licking and flinching behavior in melanoma-bearing paws within 10-30 min after the injection. This spontaneous pain was also phasic, showing a peak every hour for the first 3 h (Supplementary Fig. 11a and Supplementary Videos 1 and 2) . The same sPD-1 treatment also induced mechanical allodynia (Supplementary Fig. 11b ). Using a two-chamber test, we found that i.pl. sPD-1 treatment also resulted in marked conditioned place preference (CPP), an operant measurement of ongoing pain 35 (Fig. 8f) .
Given an importance of PD-L1 in regulating the function of immune system, we also investigated the effects of sPD-1 treatment on T cell and inflammatory markers in the ipsilateral hindpaw skin surrounding melanoma and control skin in the contralateral paw. To correlate the changes in these immune markers with pain, we collected skin tissues in the acute phase, 3 h after the sPD-1 treatment, when robust allodynia and spontaneous pain had developed. MCI-4w resulted in increased levels of mRNAs encoding T cell markers (CD2, CD3), a macrophage marker (CD68) and inflammatory cytokine markers (tumor necrosis factor, interleukin-1B, interleukin-6, interferon-γ, CCL2) in the ipsilateral skin, compared with the contralateral skin (Supplementary Fig. 12) . However, the mRNA levels of these immune and inflammatory markers did not alter after sPD-1 treatment (Supplementary Fig. 12 ). This result further indicates that sPD-1 induces pain via non-immune modulation, at least in the acute phase (first 3 h).
To further test the peripheral and neuronal function of PD-1 in regulating pain in melanoma, we employed a gene therapy method we recently established 27 in which small interfering RNA (siRNA) was used to knockdown PD-1 expression specifically in DRG neurons. This method allows siRNA uptake by DRG sensory neurons via axonal retrograde transport of siRNA 27 . Perisciatic injection of PD-1-targeting siRNA at MCI-4w induced marked and persistent mechanical allodynia for >4 d (Fig. 8g) and further evoked spontaneous pain in melanoma-bearing mice (Fig. 8h) . Compared to nontargeting control siRNA, this Pd1-targeting siRNA reduced PD-1 expression in mouse DRG and sciatic nerve but not in spinal cord tissues ( Supplementary  Fig. 13) . Thus, PD-1 expressed by DRG neurons could be sufficient to mask cancer pain.
Finally, we evaluated whether anti-PD-1 antibodies would also unmask pain similarly to sPD-1 and Pd1 siRNA in the melanoma model. 
Intravenous injection of nivolumab, but not the control human IgG4 (3-10 mg/kg), caused rapid, persistent and dose-dependent mechanical allodynia and also elicited marked spontaneous pain (Fig. 8i,j) . Furthermore, RMP1-14, a mouse anti-PD-1 antibody (10 mg/kg intravenously (i.v.)), evoked marked spontaneous pain and mechanical allodynia (Supplementary Fig. 14a,b) . In vivo recordings in the mouse sciatic nerve showed that i.v. nivolumab significantly increased spontaneous discharges in nerve fibers (Fig. 8k,l) , indicating that anti-PD-1 treatment can unmask pain by increasing the excitability of primary afferent fibers. Moreover, local injections of nivolumab via the intrathecal or intraplantar route each evoked mechanical allodynia in melanoma-bearing mice (Supplementary Fig. 14c,d) . Blocking the downstream signaling of PD-1 with the SHP-1 inhibitor SSG also elicited spontaneous pain (Supplementary Fig. 14e) . Together, these findings suggest that PD-L1 can mask pain in nonmetastatic melanoma via PD-1 and SHP (Supplementary Fig. 14f ).
DISCUSSION
The prevailing view is that cancers secrete pronociceptive mediators to activate or sensitize primary afferent neurons in the cancer -1 (i.pl.) . Left, procedure for assessing CPP in a two-chamber test. Right, difference in time spent in the drug-paired compartment between the preconditioning and postconditioning phases. *P = 0.0367, two-tailed Student's t-test, n = 7 or 8 mice per group. (g,h) Induction of mechanical allodynia (g, n = 11 mice per group) and spontaneous pain (h, n = 9 mice per group) by perisciatic injection of PD-1-targeting siRNA (2 µg) but not by control nontargeting siRNA (NT, 2 µg) given at MCI-4w. P = 0.0001, repeated-measures two-way ANOVA, followed by Bonferroni's post hoc test, *P < 0.05 (g), *P = 0.0373, two-tailed Student's t-test (h). (i,j) Intravenous nivolumab (3 and 10 mg/kg), given at MCI-4w (arrow), induces mechanical allodynia (i, n = 4-6 mice per group) and spontaneous pain 3 h after injection (j, n = 6 mice per group). P = 0.0001, repeated-measures two-way ANOVA, followed by Bonferroni's post hoc test, *P < 0.05 compared with control human IgG4 (i); *P = 0.0112, two-tailed Student's t-test (j). (k,l) Intravenous nivolumab (10 mg/kg, MCI-4w) increases spontaneous firing of afferent fibers in the sciatic nerve 3 h after the injection. (k) Discharge traces in melanoma-bearing mice treated with nivolumab and human IgG4 control. (l) Number of spikes in 2 h after the treatment. *P = 0.0280, two-tailed Student's t-test, n = 5 mice per group. Data are mean ± s.e.m. a r t I C l e S microenvironment. This microenvironment contains growth factors such as NGF and VEGF that cause sprouting of pain-sensing afferent fibers 3, 4 . In this study, we have demonstrated that cancers also produce the anti-nociceptive mediator PD-L1 to suppress pain. In particular, we uncover PD-L1 as a previously unrecognized endogenous inhibitor of pain. PD-L1 is produce not only by melanoma but also by nonmalignant tissues such as skin, DRG and spinal cord. In naive mice, exogenous application of PD-L1 induced analgesia, whereas blockade of endogenous PD-L1 and PD-1 signaling via sPD-L1, PD-1 antibodies or Pd1 deletion resulted in hyperalgesia. PD-L1 increased pain threshold via the PD-1 receptor, as the analgesic effect of PD-L1 was completely lost in mice lacking Pd1. In addition to physiological pain in naive animals, PD-L1 potently suppressed formalin-induced acute inflammatory pain. Furthermore, PD-L1 reduced chronic pain effectively, including nerve-injury-induced neuropathic pain and bone cancer pain in rodents, via both peripheral and central actions.
We have also demonstrated that PD-L1 is a neuromodulator that modulates neuronal excitability in mouse and human DRGs of the peripheral nervous system and synaptic transmission in the spinal cord of the CNS, through activation of PD-1 receptor. It is generally believed that PD-1 is expressed by immune cells such as T cells 13 . However, non-immune cells such as melanoma cells also express PD-1 (ref. 45) . Our analyses using immunohistochemistry, in situ hybridization, and electrophysiology in dissociated DRG neurons clearly demonstrate the presence of anatomical and functional PD-1 receptor in mouse and human DRG neurons.
Mechanistically, we found that activation of PD-1 by PD-L1 inhibited action potential induction and suppressed transient sodium currents in mouse and human DRG neurons. PD-L1 also regulated RMPs and caused hyperpolarization, via PD-1 and SHP activation and subsequent activation of the two-pore K + channel TREK2. Furthermore, PD-L1 was present in spinal cord tissue, and bath application of PD-L1 suppressed excitatory synaptic transmission (sEPSCs) in lamina IIo neurons in the spinal cord pain circuit. PD-L1 also inhibited bone-cancer-induced hyperexcitability in spinal WDR neurons. These results strongly suggest that as a neuromodulator PD-L1 modulates pain sensitivity by both peripheral and central mechanisms. Because PD-L1 affects both the frequency and amplitude of sEPSCs in spinal cord slices (Supplementary Fig. 6 ), PD-1 may also be present in postsynaptic neurons in the spinal cord and brain. Future study is necessary to investigate signaling mechanisms by which PD-L1-PD-1 signaling regulates synaptic transmission and synaptic plasticity in the spinal cord and brain. Given the importance of immune cells in chronic pain sensitization 10, 46 , it is conceivable that PD-L1 could control chronic pain by suppressing T-cell activation and proinflammatory responses 47 . However, given the time scale of neuromodulation (minutes to hours), the rapid changes in pain behavior after the manipulations of the PD-L1-PD-1-SHP pathway are likely to be mediated by neuronal activation. Growing evidence supports an important role of glial cells such as microglia and astrocytes in the pathogenesis of pain 10, [48] [49] [50] . We should not exclude the possibility that PD-L1 and PD-1 may also regulate glial signaling in persistent pain.
It is noteworthy that PD-L1 suppressed pathological pain not only in models of inflammatory, neuropathic and bone cancer pain but also in a melanoma model, in which mice exhibited high PD-L1 levels in circulation. We provide several lines of pharmacological and behavioral evidence to demonstrate a critical role of the PD-L1-PD-1 axis in masking pain in melanoma-bearing mice. First, inoculation of B16 melanoma cells resulted in robust melanoma growth but not in spontaneous pain or mechanical allodynia. Second, intraplantar neutralization of PD-L1 with soluble PD-1 induced spontaneous pain, ongoing pain (CPP) and mechanical allodynia, and furthermore, systemic or local injection of either human anti-PD-1 antibody (nivolumab) or mouse anti-PD-1 antibody (RMP1- 14) or siRNA knockdown of PD-1 expression in DRGs each induced robust pain symptoms in the melanoma-bearing hindpaw. Finally, inhibition of SHP also evoked spontaneous pain. It will be of great interest to investigate whether PD-L1 can still mask pain after melanoma metastasis.
What is the biological significance of PD-L1 in suppressing the function of both immune system and nociceptive system? Because these two systems are important for host defense 20, 21 , it is conceivable that the tumor can shut off both defense systems via PD-L1 secretion for optimal host invasion and cancer growth. Emerging immune therapies with anti-PD1 and anti-PD-L1 antibodies have shown efficacy in treating cancers such as melanoma 8, 15, 16 . Our findings suggest the importance of examining the pain caused by individual tumor sites in patients with melanoma and other malignancies before, after and during immune therapies. Conversely, it is also of great interest to identify new types of pain inhibitors produced by cancer cells, which will open a new avenue to developing future pain medicine. Given the high potency of PD-L1 in suppressing activities of human nociceptive neurons, local targeting of PD-L1-PD-1 signaling in sensory neurons may lead to the development of new analgesics.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Reagents. Mouse PD-1 (catalog: 1021-PD-100) and rat IgG2A isotype control (catalog: MAB006) was obtained from R&D. Mouse PD-L1 (catalog: ab180058) and human IgG4 control (catalog: ab90286) were purchased from Abcam. Nivolumab (Opdivo), a humanized anti-PD-1 antibody, was purchased from Bristol-Myers Squibb. RMP1-14 antibody to mouse PD-1 (catalog: BE0146) was from Bio X Cell. Mouse Pd1-targeting siRNA (catalog: L-040330-01-0005) and nontargeting siRNA (catalog: D-0018100-01-20) were purchased from Thermo Scientific Dharmacon. RVG peptide was synthetized by Invitrogen and mixed with siRNA to increase neuronal uptake of siRNA by axons in the sciatic nerve 27 . SHP-1 inhibitor sodium stibogluconate (SSG) was from Calbiochem (catalog: 567565). The PD1(PDCD1) cDNA construct (SC117011, NM_005018) and TREK2(KCNK10) cDNA construct (SC110477, NM_021161) were purchased from Origene Technologies.
Animals. Adult mice (males, 8-10 weeks) were used for behavioral and biochemical studies. Pd1 knockout mice with a C57BL/6 background were purchased from the Jackson Laboratory (stock no.: 021157) and maintained at the Duke animal facility. Young mice (5-7 weeks of both sexes) were used for electrophysiological studies in DRG neurons . All mouse procedures were approved by the Institutional Animal Care & Use Committee of Duke University. For the bone cancer pain experiment, adult Wistar rats (females, 8 weeks) were obtained from Shanghai Experimental Animal Center of Chinese Academy of Sciences and the rat experiments were approved by the Animal Care and Use Committee of Fudan University. All animals were housed under a 12-h light/dark cycle with food and water available ad libitum. No statistical method was used to predetermine sample size. No randomization was applied to the animal experiments. Sample sizes were estimated based on our previous studies for similar types of behavioral, biochemical and electrophysiological analyses 25, 27, 35 . Two to five mice or rats were housed in each cage. Animal experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The numbers of mice and rats used in different experiments are summarized in Supplementary Figure 15. culture of murine melanoma cells. Mouse melanoma cell line B16-F10 was obtained from ATCC (ATCCCRL-6475, Rockville, Maryland). Melanoma cells were grown in Dulbecco's modified Eagle's medium containing 4,500 mg/l glucose, 100 mg/l penicillin, 100 mg/l streptomycin and 10% FBS in 5% CO 2 /95% air at 37 °C. Cells were collected for experiments following enzymatic digestion with trypsin. We did not test for mycoplasma contamination after cell line purchase.
mouse and rat models of cancer and pain. We used the following rodent models of pain.
Mouse model of melanoma. Mouse B16-F10 melanoma cells (5 × 10 5 cells in 20 µl, suspended in PBS) were subcutaneously injected into the plantar region of the left hindpaw of a mouse.
Mouse model of inflammatory pain. Acute inflammatory pain was induced by intraplantar injection of 20 µl diluted formalin (5%).
Mouse model of neuropathic pain. Chronic constriction injury (CCI) to induce neuropathic pain was produced under isoflurane anesthesia 35 . After the left sciatic nerve was exposed, three ligatures (7-0 Prolene) were placed around the nerve proximal to the trifurcation with 1 mm between each ligature. The ligatures were loosely tied until a short flick of the ipsilateral hind limb was observed. Animals in the sham group received surgery identical to those described but without nerve ligation.
Rat bone cancer pain model. Tumor cells were extracted from the ascitic fluid of rats that received Walker 256 rat mammary gland carcinoma cells, kindly provided by Institute of Radiation Medicine, Fudan University, and a suspension of 1 × 10 8 /ml tumor cells in PBS was prepared. No mycoplasma testing was conducted in these cells. The inoculation was performed as previously described 38 . Briefly, rats were anesthetized with sodium pentobarbital (50 mg/kg, intraperitoneal). The right leg was shaved, and the skin was disinfected with iodine tincture and 75% ethanol. A 22-G needle was inserted at the site of the intercondylar eminence of the right tibia and was then replaced with a 10 µl microinjection syringe containing 4 µl of tumor cell suspension (4 × 10 5 ). The contents of the syringe were slowly injected into the tibial cavity. To prevent leakage of cells outside the bone, the injection site was sealed with bone wax. For the sham group (control), 4 µl of PBS was injected instead of carcinoma cells into the tibia. At the end of the experiment, radiological, postmortem and histological evaluations were performed. Rats that showed no obvious tumor growth and bone destruction after inoculation of tumor cells were excluded from the experiments. drug injection. For intravenous injection, anti-PD-1 antibody (nivolumab, 3 or 10 mg/kg or RMP1-14, 10 mg/kg in 100 µl PBS) or control antibody (human IgG4 or rat IgG2A) was administered into the tail vein of a mouse. For local intraplantar injection, drugs were injected in 20 µl PBS using a Hamilton microsyringe with a 30-G needle. For intrathecal injection, spinal cord puncture was made with a 30-G needle between the L5 and L6 levels to deliver reagents (10 µl) to the cerebral spinal fluid 35 . For perisciatic injection, a mixture of 2 µg siRNA and 1.5 µg of transfection reagent (chimeric rabies virus glycoprotein fragment, RVG-9R) 27 in 6 µl D5W (5% dextrose in water) was injected with a 30-G needle under the mesoneurium of the left sciatic nerve at mid-thigh level. Care was taken to avoid solution entry into the epineurium of the sciatic nerve.
In situ hybridization. We used probes directed against mouse Pdl1 (NM_021893) and Pdcd1 (NM_008798) designed by Advanced Cell Diagnostics, and the RNAscope multiplex fluorescence assay was conducted according to the manufacturer's instructions. Prehybridization, hybridization and washing were performed according to standard methods 25 .
Immunohistochemistry in mouse and human tissues and quantification. After appropriate survival times, mice were deeply anesthetized with isoflurane and perfused through the ascending aorta with PBS, followed by 4% paraformaldehyde. After the perfusion, the L4-L5 spinal cord segments, L4-L5 DRGs, sciatic nerves, and melanoma tissues were removed and postfixed in the same fixative overnight. Fresh human DRGs (L4-L5) from 4 disease-free donors from NDRI (National Disease Research Interchange) 25 and the attached spinal nerves were immediately fixed upon delivery in fresh 4% paraformaldehyde overnight. Spinal cord, DRG and nerve tissue sections 10, 14 (10 or 14 (m) and free-floating spinal cord and skin sections (30 µm) were cut in a cryostat. The sections were blocked with 2% goat or donkey serum for 1 h at room temperature and then incubated overnight at 4 °C with the following primary antibodies: anti-PD-1 (rabbit, 1:500, Sigma, catalog: PRS4065), anti-phosphorylated SHP-1 (pSHP-1, rabbit, 1:500, Abcam, catalog: ab51171), anti-NeuN (mouse, 1:1,000, Millipore, catalog: MAB377), anti-NF200 (mouse, 1:1,000, Sigma, catalog: N0142), anti-TREK2 (rabbit, 1:200, AlomoneLabs, catalog: APC-055) and anti-CGRP (goat, 1:500, Abcam, catalog: ab36001). After washing, the sections were incubated with for 2 h at room temperature with the following secondary antibodies (1:400), obtained from Jackson ImmunoResearch: Cy3-donkey anti-rabbit (catalog: 711-165-152), Cy3-donkey anti-goat (catalog: 705-165-147), FITC-donkey anti-mouse (catalog: 715-095-150), and Cy5-donkey anti-mouse (catalog: 715-175-150). For double immunofluorescence, sections were incubated with a mixture of polyclonal and monoclonal primary antibodies, followed by a mixture of Cy3-and FITC-conjugated secondary antibodies or FITC-conjugated IB4 (10 µg/ml; Sigma-Aldrich, catalog: L2895) 25 . In some cases, DAPI (1:1,000, Vector Laboratories, catalog: H-1200) or Nissl staining (1:200, ThermoFisher Scientific, catalog: N21483) was used to stain cell nuclei or neurons in tissue sections. The stained sections were examined with a Nikon fluorescence microscope, and images were captured with a CCD Spot camera. For high resolution images, sections were also examined under a Zeiss 510 inverted confocal microscope. To confirm the specificity of PD-1 antibody, blocking experiments were conducted in DRG, nerve, spinal cord and skin sections using a mixture of anti-PD-1 antibody (1:500, ~2 µg/ml) and immunizing blocking peptide (1:300, ~0.7 µg/ml; that is, ten times the molar concentration of the antibody, Sigma, catalog: SBP4065), based on a protocol recommended for blocking with immunizing peptide (http://www.abcam.com/protocols/blocking-with-immunizing-peptideprotocol-peptide-competition).
To determine whether there is neuronal loss in Pd1 deficient mice, we conducted semi-quantification of different neuronal populations in DRGs of WT and Pd1 knockout mice. All series L4 DRG sections (14 µm) were collected and every fifth section was used for the respective immunostaining (CGRP, NF200), IB4 staining or Nissl staining. The number of positive neurons for each staining was counted and the percentage of the labeled population was calculated based on
